Zavegepant Hydrochloride

Treats migraine with or without aura. Sold as Zavzpret. Every FDA application for this active ingredient.

As of Nov 15, 2026, FDA lists 1 application for Zavegepant Hydrochloride (sold as Zavzpret), first approved Mar 9, 2023, with 0 new uses approved and 0 published complete response letters.

First approved: Mar 9, 2023
Applications: 1
New uses approved: 0
Complete response letters: 0
Medicare spending, 2025: $14.9M

Medicare Spending

CMS Part D and Part B, 2025, before manufacturer rebates; matched by generic name

Product	Part	Spending, 2025	Change	Beneficiaries
Zavzpret	Part D	$14.9M	+67%	3,935

What Pharmacies Pay

Median price per unit across package codes in CMS's weekly NADAC survey, Nov 11, 2026, before rebates; see every drug's price change

ZAVZPRET 10 MG NASAL SPRAY: $190.06 per unitBrand · +5% in a year

Who Was in the Trials

1,056 participants in the largest population FDA reports for the Mar 9, 2023 approval, from FDA's Drug Trials Snapshot; see every snapshot

Women: 85%
65 and older: 4%
White: 82%
Black: 14%
Asian: 3%
Hispanic or Latino: 21%

Applications

NDAs, BLAs and generic ANDAs for this ingredient, oldest first; each opens its full history

Approved	Application	Sponsor	Supplements	Marketing
Mar 9, 2023	ZavzpretNDA 216386 · New molecular entity	Pfizer	3	Marketed

Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA